187 Matching Annotations
  1. Aug 2022
    1. Munro, A. P. S., Janani, L., Cornelius, V., Aley, P. K., Babbage, G., Baxter, D., Bula, M., Cathie, K., Chatterjee, K., Dodd, K., Enever, Y., Gokani, K., Goodman, A. L., Green, C. A., Harndahl, L., Haughney, J., Hicks, A., van der Klaauw, A. A., Kwok, J., … Appleby, K. (2021). Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): A blinded, multicentre, randomised, controlled, phase 2 trial. The Lancet, S0140673621027173. https://doi.org/10.1016/S0140-6736(21)02717-3 s

    1. Pozzetto, B., Legros, V., Djebali, S., Barateau, V., Guibert, N., Villard, M., Peyrot, L., Allatif, O., Fassier, J.-B., Massardier-Pilonchéry, A., Brengel-Pesce, K., Yaugel-Novoa, M., Denolly, S., Boson, B., Bourlet, T., Bal, A., Valette, M., Andrieu, T., Lina, B., … Trouillet-Assant, S. (2021). Immunogenicity and efficacy of heterologous ChadOx1/BNT162b2 vaccination. Nature, 1–9. https://doi.org/10.1038/s41586-021-04120-y

    1. Pritchard, E., Matthews, P. C., Stoesser, N., Eyre, D. W., Gethings, O., Vihta, K.-D., Jones, J., House, T., VanSteenHouse, H., Bell, I., Bell, J. I., Newton, J. N., Farrar, J., Diamond, I., Rourke, E., Studley, R., Crook, D., Peto, T. E. A., Walker, A. S., & Pouwels, K. B. (2021). Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Nature Medicine, 1–9. https://doi.org/10.1038/s41591-021-01410-w

    1. Sandra Ciesek. (2021, December 8). Unsere ersten Daten zur Neutralisation von Omicron versus Delta sind fertig: 2x Biontech, 2x Moderna, 1xAZ/1x Biontech nach 6 Monaten 0% Neutralisation bei Omicron, auch 3x Biontech 3 Monate nach Booster nur 25% NT versus 95% bei Delta. Bis zu 37fache Reduktion Delta vs. Omicron https://t.co/w0gHww26sg [Tweet]. @CiesekSandra. https://twitter.com/CiesekSandra/status/1468465347519041539

    1. Yaniv Erlich. (2021, December 8). Updated table of Omicron neuts studies with @Pfizer results (which did the worst job in terms of reporting raw data). Strong discrepancy between studies with live vs pseudo. Https://t.co/InQuWMAm4l [Tweet]. @erlichya. https://twitter.com/erlichya/status/1468580675007795204

    1. ReconfigBehSci. (2021, November 26). maybe this is a good moment to remind people that makers of mRNA vaccines have been extensively prepping for the possibility of new variants. Biontech/Pfizer have given a timeline of 100 days to the delivery of a retooled version of their vaccine [Tweet]. @SciBeh. https://twitter.com/SciBeh/status/1464225264523747359

  2. Apr 2022
    1. Justin Trudeau. (2021, November 22). Update: The first doses of Pfizer’s COVID-19 vaccine for kids between the ages of 5 and 11 have arrived. We’ll have 2.9 million doses in the country by the end of the week—That’s enough for every eligible child to get their first shot. So please, get your kids vaccinated. Https://t.co/sWH0fzdz5R [Tweet]. @JustinTrudeau. https://twitter.com/JustinTrudeau/status/1462613405852999687

    1. Payne, R. P., Longet, S., Austin, J. A., Skelly, D. T., Dejnirattisai, W., Adele, S., Meardon, N., Faustini, S., Al-Taei, S., Moore, S. C., Tipton, T., Hering, L. M., Angyal, A., Brown, R., Nicols, A. R., Gillson, N., Dobson, S. L., Amini, A., Supasa, P., … Zawia, A. A. T. (2021). Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell, 184(23), 5699-5714.e11. https://doi.org/10.1016/j.cell.2021.10.011

    1. Alex Sigal [@sigallab]. (2021, December 7). We have completed our first experiments on neutralization of Omicron by Pfizer BNT162b2 vaccination elicited immunity Manuscript available at https://sigallab.net and should be available on medRxiv in the coming days [Tweet]. Twitter. https://twitter.com/sigallab/status/1468325159501287434

    1. Pérez-Then, E., Lucas, C., Monteiro, V. S., Miric, M., Brache, V., Cochon, L., Vogels, C. B. F., Cruz, E. D. la, Jorge, A., Santos, M. D. los, Leon, P., Breban, M. I., Billig, K., Yildirim, I., Pearson, C., Downing, R., Gagnon, E., Muyombwe, A., Razeq, J., … Iwasaki, A. (2021). Immunogenicity of heterologous BNT162b2 booster in fully vaccinated individuals with CoronaVac against SARS-CoV-2 variants Delta and Omicron: The Dominican Republic Experience (p. 2021.12.27.21268459). medRxiv. https://doi.org/10.1101/2021.12.27.21268459

    1. Peter Navarro. (2021, August 23). This is what caving to political pressure looks like. Pfizer vaccine is leady and non-durable and risks are mounting. If we had tried to pulled this kind of sh**T in the Trump White...fill in blank. F.D.A. Grants Full Approval https://t.co/6r10euQPus [Tweet]. @RealPNavarro. https://twitter.com/RealPNavarro/status/1429833643808145408

    1. Abu-Raddad, L. J., Chemaitelly, H., Ayoub, H. H., AlMukdad, S., Tang, P., Hasan, M. R., Coyle, P., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Al-Kanaani, Z., Al-Kuwari, E., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul-Rahim, H. F., Nasrallah, G. K., Al-Kuwari, M. G., … Bertollini, R. (2022). Effectiveness of BNT162b2 and mRNA-1273 COVID-19 boosters against SARS-CoV-2 Omicron (B.1.1.529) infection in Qatar (p. 2022.01.18.22269452). medRxiv. https://doi.org/10.1101/2022.01.18.22269452

  3. Mar 2022
  4. Feb 2022
  5. Jan 2022
  6. Dec 2021
  7. Nov 2021
  8. Oct 2021
    1. Andreano, E., Paciello, I., Piccini, G., Manganaro, N., Pileri, P., Hyseni, I., Leonardi, M., Pantano, E., Abbiento, V., Benincasa, L., Giglioli, G., De Santi, C., Fabbiani, M., Rancan, I., Tumbarello, M., Montagnani, F., Sala, C., Montomoli, E., & Rappuoli, R. (2021). Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants. Nature, 1–7. https://doi.org/10.1038/s41586-021-04117-7

    1. Hulme, W. J., Williamson, E. J., Green, A., Bhaskaran, K., McDonald, H. I., Rentsch, C. T., Schultze, A., Tazare, J., Curtis, H. J., Walker, A. J., Tomlinson, L., Palmer, T., Horne, E., MacKenna, B., Morton, C. E., Mehrkar, A., Fisher, L., Bacon, S., Evans, D., … Goldacre, B. (2021). Comparative effectiveness of ChAdOx1 versus BNT162b2 COVID-19 vaccines in Health and Social Care workers in England: A cohort study using OpenSAFELY [Preprint]. Epidemiology. https://doi.org/10.1101/2021.10.13.21264937

  9. Sep 2021
  10. Aug 2021
  11. Jul 2021
    1. Elisabeth Mahase. (2021, July 26). At least 6 weeks between Pfizer vaccine doses = higher neutralising antibody levels (than a 3-4 wk interval) For those with the delta variant, antibody levels were 2.3-fold higher with the longer interval Preprint from @pitchstudy @bmjlatest https://t.co/E3yOTqNgpa [Tweet]. @emahase. https://twitter.com/emahase_/status/1419604658344112130

    1. Regev-Yochay, G., Amit, S., Bergwerk, M., Lipsitch, M., Leshem, E., Kahn, R., Lustig, Y., Cohen, C., Doolman, R., Ziv, A., Novikov, I., Rubin, C., Gimpelevich, I., Huppert, A., Rahav, G., Afek, A., & Kreiss, Y. (2021). Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel. The Lancet Regional Health - Europe, 7, 100150. https://doi.org/10.1016/j.lanepe.2021.100150

  12. Jun 2021
  13. May 2021
    1. Eric Topol. (2021, May 1). Downgrading the concern on B.1.617, the poorly named ‘double mutant’—98% effectiveness of mRNA vaccine in an Israeli outbreak @CT_Bergstrom https://t.co/tGbuwPUmAL —Lab studies: Minimal immune evasion, expected full protection from vaccine @GuptaR_lab https://t.co/AIp24G0ROK https://t.co/AK20UWlDBD [Tweet]. @EricTopol. https://twitter.com/EricTopol/status/1388539223230140422

    1. David Benkeser. (2020, November 9). Another view on uncertainty associated based on Pfizer’s results. Even if you were highly skeptical about MRNA vaccines (many are [were?]) with 50% prior belief that VE ~ 0, based on an 8:86 vax:placebo case split, the posterior probability that VE > 75% is ~ 1. Https://t.co/xtBONtGHmT [Tweet]. @biosbenk. https://twitter.com/biosbenk/status/1325856366225993729

  14. Apr 2021
  15. Mar 2021
  16. Feb 2021
  17. Jan 2021
  18. Dec 2020
    1. We report the preclinical development of BNT162b2, a lipid-nanoparticle (LNP) formulated N1-methyl-pseudouridine (m1Ψ) nucleoside-modified mRNA (modRNA) vaccine candidate that encodes P2 S with a native furin cleavage site resulting in the S1 and S2 cleavage fragments
    2. To generate the template for RNA synthesis, a DNA fragment encoding the SARS-CoV-2 P2 279 S protein (based on GenBank: MN908947), including the amino acid exchanges K986P and 280 V987P, was cloned into a starting plasmid vector with backbone sequence elements for 281 improved RNA stability and translational efficiency19,34

      BNT162b2

  19. Nov 2020